PDCD1 and skin squamous cell carcinoma: Pembrolizumab, another anti-PD-1 monoclonal antibody, was approved for use in recurrent, metastatic, and locally advanced cSCC not treatable with surgery or radiation, based on the KEYNOTE-629 trial (NCT03284424).